Benralizumab 30 mg for Nasal Polyps

Phase-Based Progress Estimates
Research Site, White Marsh, MDNasal PolypsBenralizumab 30 mg - Biological
18 - 75
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether the drug benralizumab can help treat patients with severe nasal polyposis. The trial is double-blind, meaning that neither the patients nor the researchers will know who is receiving the drug and who is receiving the placebo. The trial is international, meaning it will be conducted in multiple countries.

Eligible Conditions
  • Nasal Polyps

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: Week 56

Baseline and Week 56
Nasal Polyp Burden
Baseline and week 56
Administration, Intranasal
Week 56
Assessment the safety and tolerability of benralizumab
Disease specific health-related quality of life (HRQoL)
Nasal Polyp Surgery
Sense of Smell
Sinus Opacification by CT Scan
Symptoms associated with CRSwNP
Systemic corticosteroid (SCS) use

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

276 Total Participants · 2 Treatment Groups

Primary Treatment: Benralizumab 30 mg · Has Placebo Group · Phase 3

Experimental Group · 1 Intervention: Benralizumab 30 mg · Intervention Types: Biological
PlaceboComparator Group · 1 Intervention: Matched placebo · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 56

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,019 Previous Clinical Trials
240,380,872 Total Patients Enrolled
5 Trials studying Nasal Polyps
1,129 Patients Enrolled for Nasal Polyps
Luo Zhang, Prof. Dr.Principal InvestigatorBeijing Tongren Hospital

Eligibility Criteria

Age 18 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have been diagnosed with asthma by a doctor.
You have either undergone surgery for chronic rhinosinusitis with nasal polyps or have received treatment with systemic corticosteroids in the past.
You have had symptoms for at least 12 weeks before joining the study.

Frequently Asked Questions

Does this research project exclude elderly patients?

"Eligibility requirements for this particular clinical trial state that potential patients must be between 18-75 years old. There are alternative medical trials available for those outside of this age range: 6 for children and 62 for adults over 65." - Anonymous Online Contributor

Unverified Answer

What sets this research apart from other similar investigations?

"Benralizumab 30 mg is being trialed in 20 different ongoing studies across 352 cities and 42 countries. The first study was completed in 2014 and involved 20 patients. 43 studies have been completed in total." - Anonymous Online Contributor

Unverified Answer

Does Benralizumab 30 mg have any negative side effects?

"Given that this is a Phase 3 trial with both efficacy and safety data, Benralizumab 30 mg was rated a 3 for safety by our team at Power." - Anonymous Online Contributor

Unverified Answer

Are there any other ongoing research projects using Benralizumab at a dose of 30 mg?

"Benralizumab 30 mg was first trialed in 2014 at National Institutes of Health Clinical Center. As of now, 43 studies have been completed with 20 more underway. Of these 20, a considerable amount are taking place in Boston, Massachusetts." - Anonymous Online Contributor

Unverified Answer

What treatments or techniques are being tested in this clinical trial?

"The primary outcome metric for this study, which will be assessed over a Baseline and week 56 time frame is Nasal Polyp Burden. However, Secondary outcomes include Sense of Smell ( Change from baseline in difficulty with sense of smell [DSS] score), Sinus Opacification by CT Scan (Change from baseline in Lund Mackay score), and Disease specific health-related quality of life (HRQoL) (Change from baseline in SinoNasal Outcome Test [SNOT-22] score)." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.